L’Association canadienne des patients atteints de psoriasis est heureuse d’annoncer les gagnantes et gagnants des bourses d’été en recherche sur le psoriasis. Nous vous félicitons !
Université de Toronto
Directeur de recherche : Dr Raed Alhusayen
Projet : [traduction] Enquête sur le risque de malignité chez les personnes âgées atteintes de psoriasis : le choix du traitement a-t-il une incidence sur le risque futur de malignité ?
Titre du résumé : [traduction] Enquête sur le risque de malignité chez les personnes âgées atteintes de psoriasis : le choix du traitement a-t-il une incidence sur le risque futur de malignité ?
Lay Abstract: (disponible seulement en anglais)Psoriasis is a chronic inflammatory multisystem disease that affects the regeneration of skin cells. It commonly presents on the elbows, knees, and scalp, but can occur anywhere on the human body. Affecting approximately 2-3% of the world’s population (World Health Organization), psoriasis is not just a physical disease, but also has an important emotional impact on those whom it affects. As there currently exists no cure, effective treatment is critical. However, there is still much research that needs to be done in regard to the long-term effects of different psoriasis treatment options, including the potential risk of malignancy. This, coupled with research that has shown that immune-suppressive treatment can be associated with an increased risk of malignancy, led us to explore the potential connection between psoriasis treatment and increased risk of malignancy. As there are many different treatment options for psoriasis, the purpose of our study is to investigate and identify those that may carry an increased risk of future malignancy in order to protect psoriasis patients and to provide the best care possible. Thus, our research question is: Does psoriasis treatment affect one’s future risk of malignancy? Due to data restrictions, our study will focus on outcomes in the elderly population (defined as those 70 years and older). In order to explore our research question, we will be conducting a retrospective cohort study looking at the risk of malignancy in elderly patients with psoriasis compared to the general population, and we will be conducting subgroup analysis based on psoriasis treatment and the presence of psoriatic arthritis. We will also conduct further analysis by exploring the risk of specific types of malignancies in psoriasis patients including selective solid organ and hematologic malignancies. Through conducting this study, we hope to explore and uncover the potential association between psoriasis and its different treatments on the subsequent risk of developing a malignancy, with the hope of reducing this risk.
Université de l’Alberta
Directeur de recherche : Dr Robert Gniadecki
Projet : [traduction] Imagerie corporelle tridimensionnelle des lésions psoriasiques
Titre du résumé : [traduction] Imagerie corporelle 3D des lésions psoriasiques
Lay Abstract: (disponible seulement en anglais)Psoriasis is a chronic, relapsing skin disease that affects as much as 11.4% of adults in some countries. It can have a significant negative impact on both the physical
Christine Eun Byeol Jo,
Directeur de recherche : Dr Jensen Yeung
Projet : [traduction] L’efficacité et l’innocuité du certolizumab pegol pour le traitement du psoriasis en plaques modéré à grave : comparaison entre les personnes atteintes naïves TNF-α et celles expérimentées en pratique réelle
Titre du résumé : [traduction] Est-ce qu’une seconde chance vaut la peine ? L’efficacité et de l’innocuité du certolizumab pegol pour le traitement du psoriasis en plaques modéré à grave après l’échec d’un autre anti-TNF-α
Lay Abstract : (disponible seulement en anglais)With heightened understanding of the pathogenesis of psoriasis, many biologics have been introduced to market and are now considered the mainstay treatment. One of the earliest classes of biologics that have significantly improved patient management are anti-TNF-α. However, as individual patient response to different biologics varies, not everyone responds adequately to all biologics. Therefore, biologic switching has become a common practice. Deciding on the next optimal biologic agent remains a clinical challenge with no guidelines currently available. In the case of anti-TNF-α, while some studies state it is unnecessary to switch to a different mechanism of action, others warn of a lower response rate of a second anti-TNF-α in patients who were previously unresponsive. Certolizumab pegol (CZP) is the newest anti-TNF-α that has been approved for moderate-to-severe psoriasis by Health Canada in August 2018. Surprisingly, randomized controlled trials (RCT) showed equal efficacy between anti-TNF-α naive and experienced patients, proving CZP to be a promising option even after previous anti-TNF-α failure. However, this information is limited to RCT results which due to strict inclusion and exclusion criteria may lack generalizability to the real world. For the first time ever, our team will examine the real-world efficacy and safety of switching to CZP for treatment of moderate-to-severe plaque psoriasis at two academic sites in Toronto (Women’s College Hospital and Sunnybrook Health Sciences Centre). Results from the study will significantly help patients and physicians in real-world practice by providing greater understanding of its expected outcome for patients placed in this potentially challenging clinical situation.
Université de Toronto
Directrice de recherche : Dr Dafna Gladman
Projet : [traduction] Examen de la régulation génétique et épigénétique de la CXCL10 dans la conversion du psoriasis à l’arthrite psoriasique
Titre du résumé : [traduction] Comprendre la régulation des protéines inflammatoires chez les personnes atteintes de psoriasis qui développent l’arthrite psoriasique
Lay Abstract: (disponible seulement en anglais)Psoriatic arthritis (PsA) is an inflammatory arthritis associated that develops in approximately one third of psoriasis patients. Currently, it is difficult for family physicians and dermatologists to recognize PsA, and as a result, 30-40% of individuals who have the disease are undiagnosed. The difficulty in recognizing PsA stems from the lack of a diagnostic test to identify which psoriasis patients have it, or predict which are susceptible to developing it in the future. A blood biomarker test is urgently needed to help physicians identify PsA at an early stage, so that patients can be treated in an appropriate and timely manner.
Université de Toronto
Directrice de recherche : Dr Melinda Gooderham
Projet : [traduction] Efficacité, innocuité et modifications du traitement de Guselkumab en monothérapie pour le psoriasis en plaques modéré à grave : une étude rétrospective canadienne.
Titre du résumé : [traduction] Efficacité, innocuité et modifications du traitement de Guselkumab en monothérapie pour le psoriasis en plaques modéré à grave : une étude rétrospective canadienne.
Lay Abstract: (disponible seulement en anglais)Psoriasis is a common, chronic, inflammatory skin disease that affects approximately 3% of individuals living in Western countries. Patients with psoriasis suffer from a myriad of health sequelae such as psoriatic arthritis, gastrointestinal diseases, and cardiometabolic diseases. Furthermore, psoriasis has a profoundly detrimental effect on patient’s quality of life, psychological well-being, mental health, and work productivity. There are a wide range of genetically inherited, environmental, endocrine, and immunological factors that contribute to the incidence and severity of psoriasis in each patient. Sadly, there is currently no definitive cure for psoriasis. There are therapies available that can help attenuate the gravity of the symptoms, but due to the idiosyncratic variation amongst patients, not all treatments are equally as efficacious.